Clinical trial
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant…
NCT00336713 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00336713 |
|---|---|
| Title | A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA) |
| Official title | A Multicenter, 24-52-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug |
| Interventions | Saredutant (SR48968C), Placebo |
| Enrollment | 430 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jun 14, 2006 |
| Last update posted | May 13, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: